Offering readers a deeper exploration and understanding of the relationships between service providers and their Bio and Pharma sponsors.
Erie, PA
Joined December 2015
- Tweets3.5K
- Following132
- Followers400
- Likes128
A raw material can look routine until it stops production.
Outsourced Pharma’s Deputy Editor, Jeff Buguliskis, examines 5 assumptions sponsors should challenge before supplier changes, variability or release delays derail a CDMO campaign.
outsourcedpharma.com/doc/fiv…
#CDMO #Biopharma
RNA therapeutics are advancing quickly. The outsourcing ecosystem has to advance with them.
Louis Garguilo looks at how CDMOs, academia and automation could reshape RNA development and manufacturing.
outsourcedpharma.com/doc/cdm…
#RNA #CDMO #Biopharma
Your CDMO can make it. But can the market afford it?
Deputy editor, Jeff Buguliskis, PhD, looks at why affordability should shape formulation, packaging and outsourcing decisions long before launch.
outsourcedpharma.com/doc/you…
#CDMO #Biopharma #PharmaManufacturing
🤖 Made with AI
Everyone says they want a “true partnership” with their CDMO.
But do both sides mean the same thing?
Stella Vnook and Allison Vavala take on that question in The Outsourcing Translation Game.
Watch the full vid: outsourcedpharma.com/doc/eff…
#CDMO #Biopharma #Biotech
Join us tomorrow for a great, live discussion!
Complimentary registration, thanks to Douglas Pharmaceuticals: event.on24.com/wcc/r/5477599…
#outsourcing #cdmo #pharmamanufacturing #biopharma #biotech
A partnership isn’t really tested when everything is going well. @mebottazzi explains how solving difficult problems together, helped create transformational relationships.
Watch: shorturl.at/IfoKu
#Biopharma #GlobalHealth #VaccineDevelopment #CDMO #TechTransfer
Executives say what began with the COVID-19 outbreak, and now the red flags raised over the state of the overall economy, feel like an inseparable supply-chain and outsourcing challenge. The unfortunate amalgam is expected to continue throughout 2023.
outsourcedpharma.com/doc/rec…
The EU's revised GMP Annex 1 requires a facility-specific, formally documented strategy. The span of oversight has shifted & CDMOs are finding their sterility assurance programs in a position that will require a new level of transparency.
outsourcedpharma.com/doc/cdm…
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats Report” to our readers.
outsourcedpharma.com/doc/dec…
While people don’t always think about the choreography of good scientific teamwork, some factors should be considered, and skills that can be developed to increase a drug discovery team’s overall effectiveness and the chance of success.
By @BonumTx
outsourcedpharma.com/doc/tip…
The time devoted to R&D tends to erode the patent exclusivity period attached to a drug or biological product. Contractual agreements must spell out ownership of discoveries and data uncovered during the outsourced development process. By @WithersLLP
outsourcedpharma.com/doc/out…
“We have to change the team from doing drug development internally and internal research projects to those who are now client-centric and serving the pharmaceutical industry.” What we learn when sponsors become CDMOs.
Featuring Tim Scott, @px_austin
outsourcedpharma.com/doc/whe…
Executives say what began with the COVID-19 outbreak, and now the red flags raised over the state of the overall economy, feel like an inseparable supply-chain and outsourcing challenge. The unfortunate amalgam is expected to continue throughout 2023.
outsourcedpharma.com/doc/rec…
Tim Scott traces the arc of spray drying from its advent to today’s advanced amorphous dispersion technology. Now he's back at it again, pushing the technology to even higher levels of accessibility and productivity.
#spraydrying #smallmolecules
outsourcedpharma.com/doc/pri…
The EU's revised GMP Annex 1 requires a facility-specific, formally documented strategy. The span of oversight has shifted & CDMOs are finding their sterility assurance programs in a position that will require a new level of transparency.
outsourcedpharma.com/doc/cdm…
Organizations across life sciences face a data storage dilemma: balancing the need to store and potentially monetize mushrooming amounts of data while managing IT budgets and limiting the total cost of ownership.
By @EY_Parthenon
#datastorage #data
outsourcedpharma.com/doc/how…
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats Report” to our readers.
outsourcedpharma.com/doc/dec…
The time devoted to R&D tends to erode the patent exclusivity period attached to a drug or biological product. Contractual agreements must spell out ownership of discoveries and data uncovered during the outsourced development process. By @WithersLLP
outsourcedpharma.com/doc/out…
This article looks at the needs and challenges biotech organizations face during the manufacture of therapies, how they can reduce cost, and how establishing — or not establishing — partnerships with CDMOs can help get their therapies to patients faster.
outsourcedpharma.com/doc/cdm…
Those who follow this kind of news jumped on Novo Nordisk and Catalent for what is a significant supply-chain challenge that came to light at the turn of the New Year. Now we this up, but from a different perspective.
#supplychain #NovoNordisk #CDMO
outsourcedpharma.com/doc/a-n…
